Can a cancer drug disarm Hemophilia's hidden enemy?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients with moderate-to-severe hemophilia A (factor VIII activity \<2%). * Aged 18 to 65 years, inclusive. * Positive factor VIII inhibitor detected on at least two consecutive occasions (inhibitor titer \>0.6 BU/mL). * Baseline factor VIII inhibitor titer \>10 BU/mL at the time of enrollment. Exclusion Criteria: * Known hypersensitivity to Elranatamab or any of its excipients. * Presence of other autoimmune diseases or a need for immunosuppressive therapy for reasons unrelated to this study. * History of malignancy within 5 years prior to screening, with the exception of adequately treated carcinoma in situ of the cervix or non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma. * History of severe recurrent or chronic infections, or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungal agents within 4 weeks before the first dose or during the screening period, or superficial skin infection requiring systemic therapy within 1 week before the first dose. * Clinically significant laboratory abnormalities at screening, including: 1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × the upper limit of normal (ULN). 2. Total bilirubin \>1.5 × ULN (subjects with documented Gilbert syndrome are not excluded based on this criterion); 3. Absolute neutrophil count \<1,500/mm³; 4. Hemoglobin \<9 g/dL or immunoglobulin G (IgG) \<500 mg/dL; 5. Absolute lymphocyte count \<500/mm³; 6. Creatinine clearance (CrCl) \<30 mL/min. * Positive test for HIV antibody or syphilis antibody. * Positive hepatitis B surface antigen (HBsAg); or positive hepatitis B core antibody (anti-HBc) with detectable HBV DNA by polymerase chain reaction (PCR). Subjects positive for hepatitis C virus (HCV) antibody are excluded. * Women who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study; men whose partners plan to become pregnant during the study. * Subjects with psychiatric disorders that impair their ability to provide informed consent or comply with study procedures and follow-up. * Subjects with unresolved toxicities from prior therapies before study participation. * Any other condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the study.